Postnikov 2007.
Methods | 2‐arm cross‐over design. Duration: 14 days. |
Participants | 15 children with CF aged 7 ‐ 17 years. |
Interventions | Twice‐daily versus once‐daily amikacin. Dose: 15 mg/kg/day ‐ 20 mg/kg/day in combination with ceftazidime or meropenem. |
Outcomes | Lung function (FVC, FEV1), P aeruginosa colonies, nephrotoxicity, ototoxicity, serum levels of amikacin. Measured on day 1 and day 14. |
Notes | Not clear if inhaled or IV. |